New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For FB;OCLS;KING;FIVE;EXEL;YONG;SCS;GCA;CZR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 19, 2014
17:03 EDTCZRCaesar's to turn operating unit into REIT, Bloomberg reports
Subscribe for More Information
14:25 EDTFBOptions Update; November 14, 2014
Subscribe for More Information
09:39 EDTFBActive equity options trading on open
Subscribe for More Information
07:30 EDTKINGMorgan Stanley to hold a conference
European Technology, Media & Telecoms Conference is being held in Barcelona, Spain on November 19-21.
November 18, 2014
12:54 EDTFBFacebook introduces FB Techwire breaking tech news product
Facebook, in a post to its media blog, announced the launch of FB Techwire, a resource for journalists to discover original content including breaking news, first-person analysis, photos and videos posted to Facebook by technology influencers and organizations. Reference Link
11:07 EDTFBStocks with call strike movement; DAL FB
Subscribe for More Information
10:20 EDTCZROptions with decreasing implied volatility
Subscribe for More Information
09:32 EDTFBActive equity options trading according to Track Data: AAPLTSLA TWTR FB
Subscribe for More Information
08:44 EDTFBFacebook initiated with a Long-Term Buy at Hilliard Lyons
Subscribe for More Information
07:57 EDTFBFacebook At Work unlikely to impact LinkedIn, says Wunderlich
Subscribe for More Information
06:08 EDTFBIntel's 'Mica' bracelet to feature Google alerts, AT&T data plan, Re/code says
Subscribe for More Information
November 17, 2014
16:00 EDTFBOptions Update; November 17, 2014
Subscribe for More Information
14:56 EDTFBFacebook reports solid October engagement data, says JPMorgan
12:42 EDTFBProfessional network operators slide following report on 'Facebook at Work'
Subscribe for More Information
12:03 EDTCZROptions with decreasing implied volatility
Subscribe for More Information
09:36 EDTFBActive equity options trading
Active equity options trading according to Track Data: AAPL PBR BHI GILD MU HD AMZN TSLA YHOO FB TWTR
06:30 EDTFBFacebook says reducing 'overly promotional' page posts in news feed
Facebook said on Friday that "Our goal with News Feed has always been to show people the things they want to see. That’s why we often look to people on Facebook to tell us how we can improve. As part of an ongoing survey we asked hundreds of thousands of people how they feel about the content in their News Feeds. People told us they wanted to see more stories from friends and Pages they care about, and less promotional content. What we discovered is that a lot of the content people see as too promotional is posts from Pages they like, rather than ads. This may seem counterintuitive but it actually makes sense: News Feed has controls for the number of ads a person sees and for the quality of those ads, but those same controls haven’t been as closely monitored for promotional Page posts. Now we’re bringing new volume and content controls for promotional posts, so people see more of what they want from Pages.... Beginning in January 2015, people will see less of this type of content in their News Feeds. This change will not increase the number of ads people see in their News Feeds. The idea is to increase the relevance and quality of the overall stories – including Page posts – people see in their News Feeds. This change is about giving people the best Facebook experience possible and being responsive to what they have told us. While Pages that post a lot of the content we mention above will see a significant decrease in distribution, the majority of Pages will not be impacted by this change." Reference Link
06:23 EDTFBFacebook working on 'Facebook at Work' website, FT reports
Subscribe for More Information
05:54 EDTCZRStocks with implied volatility movement; BHI CZR
Subscribe for More Information
November 16, 2014
13:12 EDTEXELExelixis announces data from trial of XL888 and vemurafenib
Exelixis announced preliminary results from a phase 1 investigator-sponsored trial, IST, evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90, HSP90, in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma. Safety and efficacy results support the further investigation of 90 mg of XL888 twice weekly, BIW and vemurafenib 960 mg twice daily,BID, in additional studies that would include a third agent. The trial results were presented today by Keiran Smalley, Ph.D., an investigator on the trial and an associate professor at H. Lee Moffitt Cancer Center, Tampa, Florida, in a late-breaking oral presentation session at the Society for Melanoma Research 2014 International Congress, which is taking place November 13-16, in Zurich, Switzerland. Based on these results, as well as findings from coBRIM, the phase 3 pivotal trial of cobimetinib, an Exelixis-discovered MEK inhibitor, and vemurafenib in previously untreated metastatic melanoma patients with a BRAF V600 mutation, the Moffitt Center plans to initiate a phase 1b IST of the triple combination of vemurafenib, cobimetinib, and XL888 in a similar patient population. “The BRAF inhibitor vemurafenib is active in BRAF-mutated malignant melanoma, but development of resistance is common. Preclinical studies led by Keiran Smalley, Ph.D. suggested that most BRAF inhibitor resistance mechanisms involve proteins that are clients of HSP90, and the preclinical evaluation of XL888 showed that it is highly active in vemurafenib-resistant melanoma models,” said Jeffrey Weber, MD, Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center and Research Institute in Tampa, FL. “The current phase 1 data show that both drugs can be given together, and compelling initial response results suggest potential cooperative activity.” “About half of metastatic melanoma patients whose tumors harbor a BRAF V600 mutation respond to vemurafenib, but most of them develop resistance and their tumors begin to regrow,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “Multiple mechanisms drive this resistance, and the team at Moffitt found that many of them involve upregulation of HSP90 client proteins that are sensitive to XL888. We look forward to supporting the Moffitt team as they continue to evaluate XL888 as part of our IST program.”
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use